Possible association between diabetes and bisphosphonate-related jaw osteonecrosis

被引:130
作者
Khamaisi, Mogher
Regev, Eran
Yarom, Noam
Avni, Batia
Leitersdorf, Eran
Raz, Itamar
Elad, Sharon
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Internal Med B, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Hadassah Med Ctr, Ctr Diabet, IL-91120 Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Oral & Maxillofacial Surg, IL-91120 Jerusalem, Israel
[4] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Oral Med, IL-91120 Jerusalem, Israel
[5] Hadassah Med Ctr, Dept Hematol, IL-91120 Jerusalem, Israel
[6] Tel Aviv Univ, Maurice & Gabriela Goldschleger Sch Dent Med, Dept Oral Med & Oral Pathol, IL-69978 Tel Aviv, Israel
关键词
D O I
10.1210/jc.2006-2036
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Bisphosphonate-related osteonecrosis (BON) of the jaws is a newly identified condition for which the exact mechanism involved in its pathogenesis remains obscure. Objective: The objective of the study was to evaluate whether diabetes mellitus (DM) may be a contributing factor in the development of BON. Design: From 2004 to 2006, 31 patients were diagnosed with BON. The diagnosis of BON was based on the medical and dental history of each patient as well as the observation of clinical signs and symptoms of this pathological process. DM was based on two consecutive fasting blood glucose levels above 7 mmol/liter. Setting: The study was completed in the Hebrew University-Hadassah Hospital referral center. Results: Of the 31 patients with BON, 18 (58%) were found to have DM or impaired fasting glucose. The proportion of diabetic patients was much higher than expected relative to the incidence of DM in the general population (14%) and compared with the proportion of diabetic patients in a control group of oncological patients treated with bisphosphonates and without BON (12%) (P = 0.00003). Conclusions: This finding indicates that DM may be a risk factor for BON and that DM patients treated with bisphosphonates should be carefully monitored. We discuss here the bone metabolic pathways characteristic of DM patients and the way in which these pathways can augment the effects of bisphosphonates.
引用
收藏
页码:1172 / 1175
页数:4
相关论文
共 19 条
[1]   Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].
Bamias, A ;
Kastritis, E ;
Bamia, C ;
Moulopoulos, LA ;
Melakopoulos, L ;
Bozas, G ;
Koutsoukou, V ;
Gika, D ;
Anagnostopoulos, A ;
Papadimitriou, C ;
Terpos, E ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587
[2]   Sketetal involvement in patients with diabetes mettitus [J].
Carnevale, V ;
Romagnoli, E ;
D'Erasmo, E .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2004, 20 (03) :196-204
[3]  
Durie BGM, 2005, NEW ENGL J MED, V353, P99
[4]   Diabetes prevalence in England, 2001 - estimates from an epidemiological model [J].
Forouhi, NG ;
Merrick, D ;
Goyder, E ;
Ferguson, BA ;
Abbas, J ;
Lachowycz, K ;
Wild, SH .
DIABETIC MEDICINE, 2006, 23 (02) :189-197
[5]   The effects of peripheral vascular disease with the osteomyelitis in the diabetic foot [J].
Hill, SL ;
Holtzman, GI ;
Buse, R .
AMERICAN JOURNAL OF SURGERY, 1999, 177 (04) :282-286
[6]   Oxidative stress by glutathione depletion induces osteonecrosis in rats [J].
Ichiseki, T ;
Ueda, Y ;
Katsuda, S ;
Kitamura, K ;
Kaneuji, A ;
Matsumoto, T .
RHEUMATOLOGY, 2006, 45 (03) :287-290
[7]  
KUMEDA Y, 2006, CLIN CALCIUM, V16, P17
[8]  
LINDSAY R, 2001, HARRISONS PRINCIPLES, P2226
[10]   Managing the care of patients with bisphosponate-associated osteonecrosis - An American Academy of Oral Medicine position paper [J].
Migliorati, CA ;
Casiglia, J ;
Epstein, J ;
Jacobsen, PL ;
Siegel, MA ;
Woo, SB .
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2005, 136 (12) :1658-1668